Article info

Original research
Prospective development and validation of a liquid immune profile-based signature (LIPS) to predict response of patients with recurrent/metastatic cancer to immune checkpoint inhibitors

Authors

  • Jian-Guo Zhou Department of Radiation Oncology, Universitätsklinikum Erlangen, Erlangen, GermanyComprehensive Cancer Center Erlangen-EMN, Erlangen, GermanyDepartment of Oncology, The Second Affiliated Hospital of Zunyi Medical University, Zunyi, China PubMed articlesGoogle scholar articles
  • Anna-Jasmina Donaubauer Department of Radiation Oncology, Universitätsklinikum Erlangen, Erlangen, GermanyComprehensive Cancer Center Erlangen-EMN, Erlangen, Germany PubMed articlesGoogle scholar articles
  • Benjamin Frey Department of Radiation Oncology, Universitätsklinikum Erlangen, Erlangen, GermanyComprehensive Cancer Center Erlangen-EMN, Erlangen, Germany PubMed articlesGoogle scholar articles
  • Ina Becker Department of Radiation Oncology, Universitätsklinikum Erlangen, Erlangen, GermanyComprehensive Cancer Center Erlangen-EMN, Erlangen, Germany PubMed articlesGoogle scholar articles
  • Sandra Rutzner Department of Radiation Oncology, Universitätsklinikum Erlangen, Erlangen, GermanyComprehensive Cancer Center Erlangen-EMN, Erlangen, Germany PubMed articlesGoogle scholar articles
  • Markus Eckstein Comprehensive Cancer Center Erlangen-EMN, Erlangen, GermanyInstitute of Pathology, Universitätsklinikum Erlangen, Erlangen, Germany PubMed articlesGoogle scholar articles
  • Roger Sun Department of Radiation Oncology, Gustave Roussy - CentraleSupélec - TheraPanacea Center of Artificial Intelligence in Radiation Therapy and Oncology, Villejuif, FranceUniversité Paris-Saclay, INSERM1030 Radiothérapie Moléculaire, Villejuif, France PubMed articlesGoogle scholar articles
  • Hu Ma Department of Oncology, The Second Affiliated Hospital of Zunyi Medical University, Zunyi, China PubMed articlesGoogle scholar articles
  • Philipp Schubert Department of Radiation Oncology, Universitätsklinikum Erlangen, Erlangen, GermanyComprehensive Cancer Center Erlangen-EMN, Erlangen, Germany PubMed articlesGoogle scholar articles
  • Claudia Schweizer Department of Radiation Oncology, Universitätsklinikum Erlangen, Erlangen, GermanyComprehensive Cancer Center Erlangen-EMN, Erlangen, Germany PubMed articlesGoogle scholar articles
  • Rainer Fietkau Department of Radiation Oncology, Universitätsklinikum Erlangen, Erlangen, GermanyComprehensive Cancer Center Erlangen-EMN, Erlangen, Germany PubMed articlesGoogle scholar articles
  • Eric Deutsch Department of Radiation Oncology, Gustave Roussy - CentraleSupélec - TheraPanacea Center of Artificial Intelligence in Radiation Therapy and Oncology, Villejuif, FranceUniversité Paris-Saclay, INSERM1030 Radiothérapie Moléculaire, Villejuif, France PubMed articlesGoogle scholar articles
  • Udo Gaipl Department of Radiation Oncology, Universitätsklinikum Erlangen, Erlangen, GermanyComprehensive Cancer Center Erlangen-EMN, Erlangen, Germany PubMed articlesGoogle scholar articles
  • Markus Hecht Department of Radiation Oncology, Universitätsklinikum Erlangen, Erlangen, GermanyComprehensive Cancer Center Erlangen-EMN, Erlangen, Germany PubMed articlesGoogle scholar articles
  1. Correspondence to Dr Udo Gaipl; Udo.Gaipl{at}uk-erlangen.de
View Full Text

Citation

Zhou J, Donaubauer A, Frey B, et al
Prospective development and validation of a liquid immune profile-based signature (LIPS) to predict response of patients with recurrent/metastatic cancer to immune checkpoint inhibitors

Publication history

  • Accepted December 22, 2020
  • First published February 16, 2021.
Online issue publication 
February 16, 2021

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.